Equities

Charles River Laboratories International Inc

Charles River Laboratories International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)201.30
  • Today's Change5.53 / 2.82%
  • Shares traded612.72k
  • 1 Year change+2.23%
  • Beta1.3736
Data delayed at least 15 minutes, as of Nov 25 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 30 2023202320222021
ASSETS
Cash And Short Term Investments277235242
Total Receivables, Net780752650
Total Inventory380256199
Prepaid expenses14889178
Other current assets, total241074.02
Total current assets1,6091,4391,274
Property, plant & equipment, net2,0341,8571,584
Goodwill, net3,0952,8502,712
Intangibles, net8649551,061
Long term investments244312201
Note receivable - long term------
Other long term assets307147150
Total assets8,1957,6037,024
LIABILITIES
Accounts payable169206198
Accrued expenses496463508
Notes payable/short-term debt000
Current portion long-term debt/capital leases5.573.682.80
Other current liabilities, total385419324
Total current liabilities1,0551,0921,033
Total long term debt2,6472,7082,664
Total debt2,6532,7112,666
Deferred income tax191216240
Minority interest624757
Other liabilities, total642565496
Total liabilities4,5984,6264,489
SHAREHOLDERS EQUITY
Common stock0.510.510.51
Additional paid-in capital1,9061,8051,718
Retained earnings (accumulated deficit)1,8871,433981
Treasury stock - common000
Unrealized gain (loss)------
Other equity, total(196)(262)(165)
Total equity3,5972,9762,535
Total liabilities & shareholders' equity8,1957,6037,024
Total common shares outstanding515150
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.